Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017
Event Details
Strongbridge will host a conference call on
About Strongbridge Biopharma
Strongbridge Biopharma is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
+1 862-596-1304
[email protected]
Investor Relations
U.S.:
Marcy Nanus
+1 646-378-2927
[email protected]
First House
Mitra Hagen Negård
+47 21 04 62 19
[email protected]
Suite 200
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Source: Strongbridge Biopharma plc